MOXCON

MOXCON

Abbreviation for:
Moxonidine Congestive Heart Failure trial

MOXCON

Cardiology A study–Moxonidine Congestive Heart Failure trial–evaluating the efficacy of central sympathetic inhibition on heart failure. See Moxonidine, SIRA.
Mentioned in ?
References in periodicals archive ?
The 4,540-patient SR Moxonidine for Congestive Heart Failure Trial (MOXCON) was halted after an interim analysis detected sharply increased morbidity and mortality in the moxonidine group, Dr.
Cohn, chair of MOXCON's executive steering committee and professor of medicine and director of the cardiovascular division at the University of Minnesota, Minneapolis.
MOXCON was a double-blind, placebo-controlled trial conducted at 425 sites in 17 countries.
An excess of hospitalizations for worsening CHF--a secondary MOXCON end point--was observed in the moxonidine-treated patients.